Stock of the Day

Today's Trend

Altimmune, Inc. (NASDAQ: ALT) shares remain under pressure and near their 52-week low as investors weigh improved financial forecasts against a lengthy, cash-intensive clinical development path.

• HC Wainwright raised its “Buy” outlook and earnings estimates. The firm improved its EPS forecasts across 2026-2030, including narrowing projected losses for 2026 to $0.56 per share from $0.63 and for 2030 to $0.15 from $0.32. The revisions suggest better anticipated cost control and operating performance, although Altimmune is still expected to remain unprofitable. MarketBeat analyst estimates
• Altimmune has advanced pemvidutide into Phase III testing for MASH. Supportive mid-stage results and regulatory guidance provide a clearer development path for the company’s lead candidate, with pivotal data expected in 2029. Success could create significant value in the metabolic-disease market. Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
• A stronger cash position supports ongoing programs. Altimmune can fund development of pemvidutide in MASH, alcohol-associated liver disease and alcohol use disorder for longer, reducing near-term liquidity concerns. Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
• The key catalyst is several years away. The 2029 MASH readout gives investors a potentially important milestone, but it also leaves substantial time for clinical, regulatory and financing developments to affect the investment case.
• Execution and funding risks remain substantial. Altimmune continues to post large losses, faces competition in obesity and liver-disease therapies, and may need additional capital before reaching commercialization. These concerns may be outweighing the more favorable analyst estimates and pipeline progress in the near term.